Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo
2019-06-18 10:27:31
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Daiichi Sankyo
2019-06-04 12:00:41
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Daiichi Sankyo
2019-06-03 12:16:24
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio
Daiichi Sankyo
2019-05-28 13:30:01
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Daiichi Sankyo
2019-05-28 13:30:01
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer
Daiichi Sankyo
2019-05-28 13:30:01
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-]
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
Daiichi Sankyo
2019-05-28 13:30:01
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
Daiichi Sankyo
2019-05-28 13:30:01
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Daiichi Sankyo
2019-05-28 13:30:01
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients
Daiichi Sankyo
2019-05-28 13:30:01
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol
More Stories
